CLINICAL TRIALS PROFILE FOR OBICETRAPIB

Clinical Trials for Obicetrapib

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT04753606 ↗	Randomized Study of Obicetrapib as an Adjunct to Statin Therapy	Completed	NewAmsterdam Pharma	Phase 2	This study will be a placebo-controlled, double-blind, randomized, phase 2 dose-finding study to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to high-intensity statin therapy.
NCT04770389 ↗	Randomized Study of Obicetrapib in Combination With Ezetimibe	Completed	NewAmsterdam Pharma	Phase 2	This study will be a placebo-controlled, double-blind, randomized, phase 2 study in participants with mild dyslipidemia to evaluate the efficacy, safety, and tolerability of obicetrapib and ezetimibe combination therapy.
NCT05142722 ↗	Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies	Not yet recruiting	NewAmsterdam Pharma	Phase 3	This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with underlying heterozygous familial hypercholesterolemia (HeFH) and/or ASCVD to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to diet and maximally tolerated lipid-lowering therapy
NCT05161715 ↗	Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease	Not yet recruiting	NewAmsterdam Pharma	Phase 2	A Phase 2a study in men and women with early Alzheimer's disease to evaluate the pharmacodynamics, pharmacokinetics and safety of obicetrapib therapy.
NCT05202509 ↗	Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease	Not yet recruiting	NewAmsterdam Pharma	Phase 3	This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD) who are not adequately controlled despite maximally tolerated lipid-lowering therapy.
NCT05266586 ↗	Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy	Not yet recruiting	NewAmsterdam Pharma	Phase 2	This study will be a placebo-controlled, double-blind, randomized, phase 2 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg, both in combination with ezetimibe 10 mg and as monotherapy, as an adjunct to high-intensity statin therapy.
NCT05421078 ↗	A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy.	Not yet recruiting	NewAmsterdam Pharma	Phase 2	This study will be a placebo-controlled, double-blind, randomized, phase 2 dose-finding study in Japanese patients to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to stable statin therapy.

Clinical Trial Conditions for Obicetrapib

Condition Name

Condition Name for
Intervention	Trials
High Cholesterol	6
Hypercholesterolemia	6
Dyslipidemias	5
Dyslipidemia	1

Condition MeSH

Condition MeSH for
Intervention	Trials
Dyslipidemias	6
Hypercholesterolemia	6
Hyperlipoproteinemia Type II	1
Cardiovascular Diseases	1

Clinical Trial Locations for Obicetrapib

Trials by Country

Trials by Country for
Location	Trials
United States	18
Netherlands	2
Japan	1

Trials by US State

Trials by US State for
Location	Trials
California	2
Texas	2
Illinois	2
Georgia	1
Florida	1

Clinical Trial Progress for Obicetrapib

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase	Trials
Phase 3	3
Phase 2	5

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase	Trials
Not yet recruiting	6
Completed	2

Clinical Trial Sponsors for Obicetrapib

Sponsor Name

Sponsor Name for
Sponsor	Trials
NewAmsterdam Pharma	8

Sponsor Type

Sponsor Type for
Sponsor	Trials
Industry	8